Prevention of stroke in patients with atrial fibrillation (AF) requires oral anticoagulation therapy. We discuss the clinical utility of the GRASP-AF tool to identify patients with AF who are suitable for oral anticoagulation on the basis of their stroke risk profile, and propose assessment using the CHA2DS2–VASc score.
References
Wilke, T. et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb. Haemost. 107, 1053–1065 (2012).
Camm, A. J. et al. 2012 focussed update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur. Heart J. 33, 2719–2747 (2012).
Cowan, C. et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart http://dx.doi.org/10.1136/heartjnl-2012-303472.
Lip, G. Y. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137, 263–272 (2010).
National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care (Royal College of Physicians, 2006).
Mant, J. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial. Lancet 370, 493–503 (2007).
Olesen, J. B., Torp-Pedersen, C., Hansen, M. L. & Lip, G. Y. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb. Haemost. 107, 1172–1179 (2012).
Banerjee, A., Lane, D. A., Torp-Pedersen, C. & Lip, G. Y. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb. Haemost. 107, 584–589 (2012).
Olesen, J. B. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb. Haemost. 106, 739–749 (2011).
Pisters, R., Nieuwlaat, R., Lane, D. A., Crijns, H. J. & Lip, G. Y. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation: a modelling analysis from the Euro Heart Survey. Thromb. Haemost. 109, 328–336 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G. Y. H. Lip is or has been a consultant for and has received honoraria from Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi–Aventis; he has also received honoraria from Astellas/Daiichi–Sankyo and Merck/Astra–Zeneca. D. A. Lane has received honoraria and grant/research support from Bayer and Boehringer Ingelheim, and is or has been a consultant and has received honoraria from BMS/Pfizer.
Rights and permissions
About this article
Cite this article
Lane, D., Lip, G. Anticoagulation for AF: can we GRASP-AF patients?. Nat Rev Cardiol 10, 241–242 (2013). https://doi.org/10.1038/nrcardio.2013.47
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.47
- Springer Nature Limited